No Prescription |
 |
 | ||
|
LEFRA Arava |
|
| ||
No Prescription » Prescription Drugs 10 » LEFRA Arava Leflunomide is used to treat rheumatoid arthritis. Leflunomide decreases the symptoms of rheumatoid arthritis and slows damage to joints caused by the disease.Leflunomide comes as a tablet to take by mouth. It is usually taken once a day. You will need to take a larger dose for the first 3 days of treatment. Follow the directions on your prescription label carefully and ask your doctor or pharmacist to explain any part you do not understand. Take leflunomide exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Buy LEFRA Arava and other Prescription Drugs 10 products online at Medstore. Buy Online at Medstore - Click Here!
About LEFRA Arava: Product Type: Prescription Drugs 10 LEFRA ( Arava Generic Leflunomide ) LEFRA (Arava Generic Leflunomide) Arava Generic Leflunomide 10mg 100 Tablets 20mg 50 Tablets 10mg 300 Tablets 10mg 600(2 x 300) Tablets 20mg 300 Tablets 20mg 600(2 x 300) Tablets Arava Generic Leflunomide LEFRA
View more Prescription Drugs 10 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
